STOCK TITAN

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

BioMarin Pharmaceutical (NASDAQ: BMRN) has scheduled its fourth quarter and full-year 2024 financial results conference call and webcast for Wednesday, February 19, 2025, at 4:30 p.m. ET. The event will be hosted by Alexander Hardy, President and Chief Executive Officer, who will discuss financial results and provide a general business update.

Participants can join via phone using U.S./Canada dial-in (800-715-9871) or International dial-in (646-307-1963) with Conference ID 1878833. A live audio webcast will be available through BioMarin's investor website. A replay will be accessible for one week following the call, with U.S./Canada replay number (800-770-2030) and International replay number (609-800-9909), Playback ID 1878833.

BioMarin Pharmaceutical (NASDAQ: BMRN) ha programmato la conferenza telefonica e la trasmissione in streaming dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per mercoledì 19 febbraio 2025, alle 16:30 ET. L'evento sarà condotto da Alexander Hardy, Presidente e Amministratore Delegato, che discuterà dei risultati finanziari e fornirà un aggiornamento generale sull'azienda.

I partecipanti possono unirsi telefonicamente utilizzando il numero U.S./Canada (800-715-9871) o il numero internazionale (646-307-1963) con l'ID conferenza 1878833. Una trasmissione audio in diretta sarà disponibile attraverso il sito web degli investitori di BioMarin. Una registrazione sarà accessibile per una settimana dopo la chiamata, con il numero di registrazione U.S./Canada (800-770-2030) e il numero di registrazione internazionale (609-800-9909), ID Playback 1878833.

BioMarin Pharmaceutical (NASDAQ: BMRN) ha programado su llamada de conferencia y transmisión en vivo de resultados financieros del cuarto trimestre y del año completo 2024 para el miércoles 19 de febrero de 2025, a las 4:30 p.m. ET. El evento será presentado por Alexander Hardy, Presidente y Director Ejecutivo, quien discutirá los resultados financieros y proporcionará una actualización general del negocio.

Los participantes pueden unirse por teléfono utilizando el número de EE. UU./Canadá (800-715-9871) o el número internacional (646-307-1963) con el ID de conferencia 1878833. Se dispondrá de una transmisión de audio en vivo a través del sitio web de inversores de BioMarin. Una grabación estará disponible durante una semana después de la llamada, con el número de grabación de EE. UU./Canadá (800-770-2030) y el número de grabación internacional (609-800-9909), ID de reproducción 1878833.

BioMarin Pharmaceutical (NASDAQ: BMRN)는 2024년 4분기 및 전체 연도 재무 실적을 발표하는 전화 회의 및 웹캐스트를 2025년 2월 19일 수요일 오후 4시 30분 (ET)에 진행합니다. 이번 이벤트는 Alexander Hardy CEO가 진행하며, 재무 실적에 대한 논의와 회사 전반에 대한 업데이트를 제공합니다.

참가자는 미국/캐나다 전화 번호 (800-715-9871) 또는 국제 전화 번호 (646-307-1963)로 회의 ID 1878833와 함께 전화로 참여할 수 있습니다. BioMarin의 투자자 홈페이지를 통해 생중계 오디오 웹캐스트에 접속할 수 있습니다. 이 통화 이후 일주일 동안 다시 듣기가 가능하며, 미국/캐나다 재생 전화 번호 (800-770-2030) 및 국제 재생 번호 (609-800-9909), 재생 ID 1878833이 제공됩니다.

BioMarin Pharmaceutical (NASDAQ: BMRN) a prévu sa conférence téléphonique et son webinaire sur les résultats financiers du quatrième trimestre et de l'année complète 2024 pour mercredi 19 février 2025, à 16h30 ET. L'événement sera animé par Alexander Hardy, Président et Directeur général, qui discutera des résultats financiers et fournira une mise à jour générale sur l'entreprise.

Les participants peuvent se joindre par téléphone en utilisant le numéro U.S./Canada (800-715-9871) ou le numéro international (646-307-1963) avec l'ID de conférence 1878833. Un webinaire audio en direct sera disponible sur le site des investisseurs de BioMarin. Un enregistrement sera accessible pendant une semaine après l'appel, avec le numéro de rediffusion U.S./Canada (800-770-2030) et le numéro de rediffusion international (609-800-9909), ID de lecture 1878833.

BioMarin Pharmaceutical (NASDAQ: BMRN) hat seine Telefonkonferenz und Webcast zu den finanziellen Ergebnissen des vierten Quartals und des Gesamtjahres 2024 für Mittwoch, den 19. Februar 2025, um 16:30 Uhr ET angesetzt. Die Veranstaltung wird von Alexander Hardy, Präsident und Geschäftsführer, geleitet, der die finanziellen Ergebnisse besprechen und ein allgemeines Unternehmensupdate geben wird.

Teilnehmer können sich telefonisch über die US-/Kanadische Einwahlnummer (800-715-9871) oder die internationale Einwahlnummer (646-307-1963) unter der Konferenz-ID 1878833 einwählen. Ein Live-Audio-Webcast wird über die Investorenseite von BioMarin verfügbar sein. Eine Aufzeichnung wird eine Woche nach dem Anruf verfügbar sein, mit der US-/Kanadischen Aufzeichnungsnummer (800-770-2030) und der internationalen Aufzeichnungsnummer (609-800-9909), Playback-ID 1878833.

Positive
  • None.
Negative
  • None.

SAN RAFAEL, Calif., Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a general business update.

Dial-in Number 
U.S. / Canada Dial-in Number: 800-715-9871
International Dial-in Number: 646-307-1963
Conference Call ID: 1878833

U.S. / Canada Replay Dial-in Number: 800-770-2030
International Replay Dial-in Number: 609-800-9909
Playback ID: 1878833 

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin
BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com

Contacts:


Investors

Media

Traci McCarty

Marni Kottle

BioMarin Pharmaceutical Inc.

 BioMarin Pharmaceutical Inc.

(415) 455-7558

 (650) 374-2803

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-fourth-quarter-and-full-year-2024-financial-results-conference-call-and-webcast-on-wednesday-february-19-2025-at-430pm-et-302368081.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

When will BioMarin (BMRN) release its Q4 and full-year 2024 earnings?

BioMarin will release its Q4 and full-year 2024 earnings on Wednesday, February 19, 2025, at 4:30 p.m. ET.

How can investors access BioMarin's (BMRN) Q4 2024 earnings call?

Investors can access the call via phone (U.S./Canada: 800-715-9871, International: 646-307-1963, ID: 1878833) or through a live webcast on BioMarin's investor website.

Will there be a replay available for BioMarin's (BMRN) Q4 2024 earnings call?

Yes, a replay will be available for one week after the call using U.S./Canada number (800-770-2030) or International number (609-800-9909) with Playback ID 1878833.

Who will host BioMarin's (BMRN) Q4 2024 earnings call?

Alexander Hardy, President and Chief Executive Officer of BioMarin, will host the earnings call and webcast.
Biomarin Pharmaceutical Inc

NASDAQ:BMRN

BMRN Rankings

BMRN Latest News

BMRN Stock Data

12.92B
188.94M
0.93%
98.62%
2.22%
Biotechnology
Pharmaceutical Preparations
Link
United States
NOVATO